Cargando…

Assessment of the clinical and cost-effectiveness evidence in the reimbursement decisions of new cancer drugs

BACKGROUND: This study aimed to describe the clinical and cost-effectiveness evidence supporting reimbursement decisions of new cancer drugs and analyze the influence of trial characteristics and the cost per quality-adjusted life years (QALYs) on the likelihood of reimbursement in Sweden. PATIENTS...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chauca Strand, G., Bonander, C., Jakobsson, N., Johansson, N., Svensson, M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2022
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9588887/ https://www.ncbi.nlm.nih.gov/pubmed/36037568 http://dx.doi.org/10.1016/j.esmoop.2022.100569

Ejemplares similares

Cancer Drugs Reimbursed with Limited Evidence on Overall Survival and Quality of Life: Do Follow-Up Studies Confirm Patient Benefits?
por: Chauca Strand, Gabriella, et al.
Publicado: (2023)

Use of health technology assessment in drug reimbursement decisions in China
por: Chen, Wen, et al.
Publicado: (2023)

Use of health technology assessment in drug reimbursement decisions in China
Publicado: (2023)

Pre-reimbursement: early assessment for coverage decisions
por: Grössmann, Nicole, et al.
Publicado: (2019)

Correlation between clinical trial endpoints of marketed cancer drugs and reimbursement decisions in China
por: Ling, Kexin, et al.
Publicado: (2022)

Drug pricing and reimbursement decision making systems in Mongolia
por: Dorj, Gereltuya, et al.
Publicado: (2017)

The reimbursement decision speed for oncology new drugs in China and its determinant factors
por: Zhu, Xingyue, et al.
Publicado: (2023)

Using multicriteria decision analysis during drug development to predict reimbursement decisions
por: Williams, Paul, et al.
Publicado: (2014)

Reporting reimbursement price decisions for onco-hematology drugs in Spain
por: Elvira, David, et al.
Publicado: (2023)

The impact of reimbursement negotiations on cost and availability of new pharmaceuticals: evidence from an online experiment
por: Wettstein, Dominik J., et al.
Publicado: (2020)

The impact of cost-sharing on prescription drug demand: evidence from a double-difference regression kink design
por: Gamba, Simona, et al.
Publicado: (2022)

Cost-analysis of XELOX and FOLFOX4 for treatment of colorectal cancer to assist decision-making on reimbursement
por: Tse, Vicki C, et al.
Publicado: (2011)

Value-Based Reimbursement Decisions for Orphan Drugs: A Scoping Review and Decision Framework
por: Paulden, Mike, et al.
Publicado: (2014)

Balancing early access with uncertainties in evidence for drugs authorized by prospective case series – systematic review of reimbursement decisions
por: Wallerstedt, Susanna M., et al.
Publicado: (2018)

Using economic evaluations to support acupuncture reimbursement decisions: current evidence and gaps
por: Li, Hongchao, et al.
Publicado: (2022)

Association of Supporting Trial Evidence and Reimbursement for Off-Label Use of Cancer Drugs
por: Herbrand, Amanda Katherina, et al.
Publicado: (2021)

Reimbursement Legislations and Decision Making for Orphan Drugs in Central and Eastern European Countries
por: Malinowski, Krzysztof Piotr, et al.
Publicado: (2019)

Drug pricing and reimbursement information management: processes and decision making in the global economy
por: Tsourougiannis, Dimitrios
Publicado: (2017)

Conflict of interest in Health Technology Assessment decisions: case law in France and impact on reimbursement decisions
por: Frybourg, Sandrine, et al.
Publicado: (2015)

Assessing potential prescription reimbursement changes: Estimated acquisition costs in Wisconsin
por: Kreling, David H.
Publicado: (1989)

Approval, reimbursement and pricing of high-cost cancer medicines in Australia
por: Vitry, Agnes
Publicado: (2015)

Outdated criteria for drug plan reimbursement obstruct evidence-based care
por: Bayoumi, Ahmed, et al.
Publicado: (2021)

A System for Cost and Reimbursement Control in Hospitals
por: Fetter, Robert B., et al.
Publicado: (1976)

Nursing Home Cost Studies and Reimbursement Issues
por: Bishop, Christine E.
Publicado: (1980)

Cost Analysis and Reimbursement of Weightbearing Computed Tomography
por: Alexander, Nathaniel B., et al.
Publicado: (2023)

“Budget Impact Analyses”: A Practical Policy Making Tool for Drug Reimbursement Decisions
por: Jamshidi, Hamid Reza, et al.
Publicado: (2014)

Effects of primary care cost-sharing among young adults: varying impact across income groups and gender
por: Johansson, Naimi, et al.
Publicado: (2019)

Weighing of Evidence by Health Technology Assessment Bodies: Retrospective Study of Reimbursement Recommendations for Conditionally Approved Drugs
por: Vreman, Rick A., et al.
Publicado: (2018)

Cancer therapy: reimbursement of new therapeutic technologies.
por: Williams, H. M.
Publicado: (1992)

Role of centralized review processes for making reimbursement decisions on new health technologies in Europe
por: Stafinski, Tania, et al.
Publicado: (2011)

Do Health Technology Assessment organisations consider manufacturers’ costs in relation to drug price? A study of reimbursement reports
por: Enzing, Joost J., et al.
Publicado: (2022)

Access to innovative drugs and the National Reimbursement Drug List in China: Changing dynamics and future trends in pricing and reimbursement
por: Macabeo, Bérengère, et al.
Publicado: (2023)

Cost and Outcomes of Medicare Reimbursement for HMO Preventive Services
por: Patrick, Donald L., et al.
Publicado: (1999)

Assessment of Methodological Quality of Economic Evaluations in Belgian Drug Reimbursement Applications
por: Simoens, Steven
Publicado: (2013)

Reimbursement of Orphan Drugs in Europe in Relation to the Type of Authorization by the European Medicines Agency and the Decision Making Based on Health Technology Assessment
por: Malinowski, Krzysztof Piotr, et al.
Publicado: (2018)

The reimbursement coverage decisions and pricing rules for medical devices in Taiwan
por: Tsai, Hsin-Yi, et al.
Publicado: (2022)

Evidence on the cost of breast cancer drugs is required for rational decision making
por: Berghuis, Anne Margreet Sofie, et al.
Publicado: (2018)

Description of the use of multicriteria to support pricing and reimbursement decisions by European health technology assessment bodies
por: Elvira, David, et al.
Publicado: (2021)

Informed decision‐making: Statistical methodology for surrogacy evaluation and its role in licensing and reimbursement assessments
por: Weir, Christopher J., et al.
Publicado: (2022)

TAILORED ACTIVITY PROGRAM (TAP) COSTS: OPPORTUNITIES TO STREAMLINE DELIVERY AND PURSUE REIMBURSEMENT
por: Pizzi, Laura T, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_lq7a036kp0l8ng3reesjq2rmra